Devasis Panda

Devasis Panda

Auto-generated profile, based on publicly available information

Devasis Panda

Department of Pathology Rajiv Gandhi Cancer Institute and Research Centre New Delhi India

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
PTPrashant Ramesh Tembhare
Prashant Ramesh Tembhare
HSHarshini Sriram
Harshini Sriram
TKTwinkle Khanka
Twinkle Khanka
GCGaurav Chatterjee
Gaurav Chatterjee
DPDevasis Panda
Devasis Panda
PSPapagudi G Subramanian
Papagudi G Subramanian
Background Recently, anti-CD38 monoclonal antibody (Mab) therapy has become a focus of attention as an additional/alternative option for many hematological neoplasms including T-cell acute lymphoblastic leukemia (T-ALL). It has been shown that antitumor efficacy of anti-CD38-Mab depends on the level of CD38 expression on tumor cells. Reports on CD38 expression in T-ALL are scarce, and data on the effect of cytotoxic chemotherapy on CD38 expression are limited to very few samples. Moreover, it lacks entirely in refractory disease and in adult T-ALL. We report the flow cytometric evaluation of CD38 expression in T-ALL blasts at diagnosis and the effect of cytotoxic chemotherapy on its expression in measurable residual disease (MRD), refractory disease (MRD≥5%), and relapsed disease in a large cohort of T-ALL. Methods The study included 347 samples (188 diagnostic, 100 MRD, 24 refractory and 35 relapse samples) from 196 (children: 85; adolescents/adults: 111) patients with T-ALL. CD38-positive blasts percentages (CD38-PBPs) and expression-intensity (mean fluorescent intensity, CD38-MFI) were studied using multicolor flow cytometry (MFC). MFC-based MRD was performed at the end-of-induction (EOI-MRD, day 30–35) and end-of-consolidation (EOC-MRD, day 78–85) subsequent follow-up (SFU-MRD) points. Results Patients were classified into early thymic precursor subtype of T-ALL (ETPALL, 54/188, 28.7%), and non-ETPALL (134/188, 71.3%). Of 188, EOI-MRD assessment was available in 152, EOC-MRD was available in 96 and SFU-MRD was available in 14 patients. CD38 was found positive in 97.9% (184/188) of diagnostic, 88.7% (110/124) MRD (including 24-refractory) and 82.9% (29/35) relapsed samples. Median (95% CI) of CD38-PBPs/MFI in diagnostic, MRD, refractory, and relapsed T-ALL samples were, respectively, 85.9% (82.10%–89.91%)/4.2 (3.88–4.47), 74.0% (58.87%–83.88%)/4.6 (3.67–6.81), 79.6% (65.25%–96.11%)/4.6 (3.33–8.47) and 85.2% (74.48%–93.01%)/5.6 (4.14–8.99). No significant difference was noted in CD38 expression between pediatric versus adult and patients with ETPALL versus non-ETPALL. No change was observed in CD38-MFI between diagnostic versus MRD and diagnostic versus relapsed paired samples. However, we noticed a mild drop in the CD38-PBPs in MRD samples compared with the diagnostic samples (p=0.016). Conclusion We report an in-depth analysis of CD38 expression in a large cohort of T-ALL at diagnosis, during chemotherapy, and at relapse. Our data demonstrated that CD38 is robustly expressed in T-ALL blasts with a little effect of cytotoxic chemotherapy making it a potentially effective target for antiCD38-Mab therapy.

19 August 2020 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
PTPrashant R. Tembhare
Prashant R. Tembhare
GCGaurav Chatterjee
Gaurav Chatterjee
TKTwinkle Khanka
Twinkle Khanka
SGSitaram Ghogale
Sitaram Ghogale
YBYajamanam Badrinath
Yajamanam Badrinath
PSPapagudi G. Subramanian
Papagudi G. Subramanian

31 August 2020 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
DPDevasis Panda
Devasis Panda
GCGaurav Chatterjee
Gaurav Chatterjee
RSRohan Sardana
Rohan Sardana
TKTwinkle Khanka
Twinkle Khanka
SGSitaram Ghogale
Sitaram Ghogale
PTPrashant R. Tembhare
Prashant R. Tembhare

8 September 2020 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
GCGaurav Chatterjee
Gaurav Chatterjee
HSHarshini Sriram
Harshini Sriram
SGSitaram Ghogale
Sitaram Ghogale
NDNilesh Deshpande
Nilesh Deshpande
TKTwinkle Khanka
Twinkle Khanka
PTPrashant R. Tembhare
Prashant R. Tembhare

1 August 2020 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
DPDevasis Panda
Devasis Panda
GCGaurav Chatterjee
Gaurav Chatterjee
TKTwinkle Khanka
Twinkle Khanka
SGSitaram Ghogale
Sitaram Ghogale
YBYajamanam Badrinath
Yajamanam Badrinath
PTPrashant R. Tembhare
Prashant R. Tembhare

8 March 2024 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
NDNupur Das
Nupur Das
DPDevasis Panda
Devasis Panda
SGSmeeta Gajendra
Smeeta Gajendra
RGRitu Gupta
Ritu Gupta
DTDeepshi Thakral
Deepshi Thakral
SSSaroj Singh
Saroj Singh